BioSyntech announces exercise of over-allotment option



    /THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT
    INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR
    DISSEMINATION IN THE UNITED STATES/

    LAVAL, QC, July 18 /CNW/ - BioSyntech, Inc. (the "Company") (TSX:BSY) is
pleased to announce that as part of the exercise of the over-allotment option
in its previously announced bought deal, the Company has sold to a syndicate
led by Dundee Securities Corporation and including Macquarie Capital Markets
Canada Ltd., Versant Partners Inc. and Laurentian Bank Securities Inc., an
aggregate of 1,550 Units, each comprised of $1,000 principal amount of
subordinated secured convertible debentures and 2,500 common share purchase
warrants, representing aggregate gross additional proceeds of $1,550,000 to
the Company. As a result, total aggregate gross proceeds to the Company from
the financing increased to $12,550,000.

    THE SECURITIES OFFERED HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES
ACT OF 1933, AS AMENDED, AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES
ABSENT REGISTRATION OR AN APPLICABLE EXEMPTION FROM THE REGISTRATION
REQUIREMENTS. THIS PRESS RELEASE SHALL NOT CONSTITUTE AN OFFER TO SELL OR THE
SOLICITATION OF AN OFFER TO BUY THE SECURITIES, NOR SHALL THERE BE ANY SALE OF
THE SECURITIES IN ANY STATE IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE
UNLAWFUL.

    FORWARD-LOOKING STATEMENTS

    This press release contains forward-looking statements and information
which are subject to material risks and uncertainties. Such statements are not
historical facts and are based on the current expectations of management. You
are cautioned that such statements are subject to a multitude of risks and
uncertainties that could cause actual results, future circumstances, or events
to differ materially from those projected in the forward-looking information.
These risks include, but are not limited to, those associated with our
capacity to finance our activities, the dilution for existing shareholders
resulting from such financings, the adequacy, timing, and results of our
clinical trials, the regulatory approval process, competition, securing and
maintaining corporate alliances, market acceptance of the Corporation's
products, the availability of government and insurance reimbursements for the
Corporation's products, the strength of intellectual property, the success of
research and development programs, reliance on subcontractors and key
personnel, and other risks and uncertainties detailed from time-to-time in our
filings with the Canadian securities commissions.
    Readers should not place undue reliance on the forward-looking
information, given that (i) our actual results could differ materially from a
conclusion, forecast or projection in the forward-looking information, and
(ii) certain material factors or assumptions which were applied in drawing a
conclusion or making a forecast or projection as reflected in the
forward-looking information, could prove to be inaccurate. Additional
information is contained in the Corporation's annual report and other
documents filed from time to time with the Canadian securities commissions
which are available at www.sedar.com. These statements speak only as of the
date they are made, and we assume no obligation to revise such statements as a
result of any event, circumstance or otherwise, except in accordance with law.

    %SEDAR: 00020217EF




For further information:

For further information: Claude LeDuc, President and CEO, BioSyntech
Inc., (450) 686-2437; François Michaud, CFO, BioSyntech Inc., (450) 686-2437

Organization Profile

BIOSYNTECH, INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890